Ethiopia to get 300,000 doses of Sinopharm COVID-19 shot, health minister says
Reuters
Published Mar 29, 2021 09:08AM ET
NAIROBI (Reuters) - Ethiopia on Monday said it would receive 300,000 COVID-19 vaccine doses from China's state-backed China National Pharmaceutical Group (Sinopharm) on Tuesday.
The Sinopharm doses are the first shots Ethiopia has secured outside the global COVAX vaccine-sharing initiative, Health Minister Lia Tadesse told Reuters in a text message.
Ethiopia is struggling to administer shots and tame infections that have spiked.
In the past month, it has recorded a 26% increase in coronavirus infections and deaths rose by 18%, health ministry data shows. On Thursday, Africa's disease control body, the Africa CDC, said Ethiopia had reported the highest number of new cases in the last week of any country on the continent.
With a population of over 110 million, the Horn of Africa nation has recorded 200,563 infections and 2,801 deaths since its first case was announced in March last year.
On Monday, Johnson & Johnson (NYSE:JNJ) said it had agreed to supply up to 400 million doses of its COVID-19 vaccine to the African Union (AU) from the third quarter of 2021.
On March 7, Ethiopia received nearly 2.2 million doses of the AstraZeneza vaccine through COVAX.
In February the minister said Ethiopia hoped to inoculate at least a fifth of the country’s 110 million people by the end of the year.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.